17P - Efficacy and safety of furmonertinib as salvage treatment for EGFR-mutated NSCLC patients progressed on third-generation EGFR TKIs

Background

The current standard treatment for EGFR mutated NSCLC patients progressed on third-generation EGFR TKI was chemotherapy. For patients retaining EGFR mutations after resistance, switching to more potent TKI provided another strategy. Furmonertinib was designed with unique chemical structure to improve potency and specificity targeting various EGFR mutations, and has been verified its superior efficacy and favorable safety profile in clinical trials. This study described the real-world efficacy and safety of furmonertinib as salvage treatment for EGFR-mutated NSCLC patients progressed on other third-generation EGFR TKIs.

Methods

We retrospectively examined advanced NSCLC patients with EGFR mutations progressed on osimertinib and/or aumolertinib who were treated with furmonertinib with or without other treatment from Apr 12, 2021, to Dec 20, 2023. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and safety were assessed.

Results

We included 43 patients, of which 37.2% progressed on first-line 3^rd generation EGFR TKI, 23.2% patients failed to both osimertinib and aumolertinib, and 37.2% patients progressed in intracranial lesion. The median follow-up time was 6.1 months (range 0.9 - 27.1). The ORR and DCR were 18.6% and 79.1% respectively, the median PFS was 6.1 months (95% CI 4.2 - 8.0). In those patients received furmonertinib after failure of first-line 3^rd generation EGFR TKI, the ORR and DCR were 25% and 87.5% respectively, the median PFS was 10.5 months (95% CI 0.0 - 23.6). In addition, treatment-emergent adverse events (TEAEs) of any grade occurred in 4.7% of patients (2/43), with no grade ≥3 TEAE was observed.

Conclusions

Furmonertinib showed encouraging anti-tumor activity and an acceptable safety profile as salvage treatment for patient with EGFR mutated NSCLC progressed on 3^rd generation EGFR TKI, especially in those with first-line 3^rd generation EGFR TKI.

Legal entity responsible for the study

The authors.

Funding

1. Guangzhou Science and Technology Program (grant number: 202002020074) 2. Natural Science Foundation of Guangdong Province (grant number: 2022A1515012582).

Disclosure

All authors have declared no conflicts of interest.